Ovid Therapeutics (OVID) Debt Ratio (2019 - 2020)
Ovid Therapeutics' (OVID) quarterly Debt Ratio came in at 0.03 in Q4 2020, up 770.89% on a YoY basis from 0.0 in Q1 2020, and up 919.78% quarter-over-quarter from 0.0 in Q3 2020.
Powered by 
Analysis
Ovid Therapeutics (OVID) Debt Ratio (2019 - 2020) Analysis & Trends
Ovid Therapeutics (OVID) has reported Debt Ratio for 2 consecutive years, with 0.03 the latest figure, recorded in Q4 2020.
- For the quarter ending Q4 2020, Debt Ratio rose 770.89% year-over-year to 0.03; the trailing twelve-month figure through Dec 2020 stood at 0.03 (up 770.89% YoY), and the FY2020 full-year result was 0.03, up 770.89% from the prior year.
- Debt Ratio improved to 0.03 in Q4 2020 per OVID's latest filing, from 0.0 in the prior quarter.
- Across five years, Debt Ratio topped out at 0.03 in Q4 2020 and bottomed at 0.0 in Q3 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 0.30 |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 0.52 |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | 0.42 |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | 0.08 |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | 0.31 |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | 0.17 |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn | 0.12 |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 0.00 |
| 10 | Ovid Therapeutics | 517.32 Mn | 400.10 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2020 | 0.03 |
| Sep 30, 2020 | 0.00 |
| Jun 30, 2020 | 0.01 |
| Mar 31, 2020 | 0.00 |
| Dec 31, 2019 | 0.00 |
| Sep 30, 2019 | 0.02 |
| Jun 30, 2019 | 0.02 |
| Mar 31, 2019 | 0.02 |